Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855
Symptomatic Neurogenic Orthostatic Hypertension, nOH

About this trial
This is an interventional treatment trial for Symptomatic Neurogenic Orthostatic Hypertension focused on measuring Symptomatic neurogenic orthostatic hypertension, hepatic impairment
Eligibility Criteria
Inclusion Criteria:
All Subjects:
- has a body mass index (BMI) of 19 to 40 kg/m2, inclusive, and weight of at least 55 kg.
- clinical labs within normal ranges
- creatinine clearance of >70 mL/min
- women must be non-pregnant and non-lactating, male and females must agree to highly effective methods of contraception
- additional criteria apply
Subjects with Impaired Hepatic Function additional criteria:
- Subject has mild (Child-Pugh Class A [5 to 6 points]), moderate (Child-Pugh Class B [7 to 9 points]), or severe (Child-Pugh Class C [10-15 points]) liver disease
- has stable hepatic impairment defined as no clinically significant change in disease status within the last 30 days
- must be on a stable dose of medication and/or treatment regimen at least 30 days before dosing
- Additional inclusion criteria apply
Exclusion Criteria:
Subjects with normal hepatic function:
- history of reactions or hypersensitivity to ampreloxetine or known intolerance to other norepinephrine reuptake inhibitors (NRI) or serotonin norepinephrine reuptake inhibitors (SNRI).
- personal or family history of congenital long QT syndrome
- history of untreated closed angle glaucoma
- history of orthostatic hypotension or orthostatic tachycardia or a history of dizziness, lightheadedness or fainting, or a feeling of blacking out upon standing
- has used nephrotoxic or hepatotoxic medications 30 days before Day-2
- routinely uses more than 2 grams of acetaminophen daily
- has used tobacco-containing products (e.g., cigarettes, cigars, chewing tobacco, snuff, e cigarettes, vaporizers) within 3 months before Screening or has a positive cotinine result at Screening or Day -2
- used any CYP1A2 inhibitor or inducer within 7 days or 5 half lives, whichever is longer, prior to ampreloxetine dosing or requires concomitant use
- has used monoamine oxidase inhibitors (MAO-I) within 7 days or 5 half lives, whichever is longer, prior to ampreloxetine dosing or requires concomitant use
- additional exclusion criteria apply
Subjects with impaired hepatic function additional criteria:
- has severe ascites that could potentially interfere with respiratory function
- current severe hepatic encephalopathy
- history of liver transplantation, hepatocellular carcinoma, or acute liver disease
- has biliary liver cirrhosis
- has uncontrolled hypertension (SBP >180 mm Hg and DBP (Diastolic blood pressure) >110 mm Hg)
- has an abnormal ECG at Screening or Day -2, including QTcF (Fridericia's corrected QT Interval) >470 msec
- additional exclusion criteria apply
Sites / Locations
- Theravance Biopharma Investigational Site
- Theravance Biopharma Investigational Site
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Experimental
Experimental
Normal Hepatic Function
Mild Hepatic Function
Moderate Hepatic Function
Severe Hepatic Function
Ampreloxetine Dose A single dose administration to subjects with normal hepatic function
Ampreloxetine Dose A single dose administration to subjects with mild hepatic impairment
Ampreloxetine Dose A single dose administration to subjects with moderate hepatic impairment
Ampreloxetine Dose A single dose administration to subjects with severe hepatic impairment